Amgen To Re-Launch AMG 706 Phase II Enrollment, Phase III Still Delayed
Executive Summary
Amgen will re-launch enrollment of head-to-head Phase II studies for its oncologic AMG 706 after concerns were raised about the potential development of cholecystitis, although the Phase III trials remain indefinitely delayed